U086 - Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology
Monday, February 19; 4:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Identify and describe a new class of medications that will be useful in dermatology
- Utilize JAK inhibitors for the treatment of alopecia areata, vitiligo and atopic dermatitis
- Summarize the potential adverse effects of JAK inhibitors
Effective treatments for alopecia areata, vitiligo and atopic dermatitis are limited. The recent development of Janus kinase inhibitors with their unique mechanism of action has led to new therapeutic options in dermatology. The application of Janus kinase inhibitors to three common dermatologic diseases will be presented, including the results of clinical trials and case series. Safety will be discussed. The audience for this session will be dermatologists whose practice involves the care of patients with these common dermatoses.
- King, Brett Andrew, MD, PhD: Aclaris Therapeutics Inc. – A(H); Celgene – A(H); Concert Pharmaceuticals – C(Fees); Eli Lilly and Company – C(Fees); Pfizer Inc. – A(H), C(Fees); Regeneron – A(H);
- Lotsoff, Ava: no financial relationships exist with commercial interests.
- Lotsoff, Monica: no financial relationships exist with commercial interests.
Monday, February 19
Dr. King / Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology